Quantcast

Latest Paroxysmal nocturnal hemoglobinuria Stories

2014-05-09 12:26:33

WASHINGTON, May 9, 2014 /PRNewswire-USNewswire/ -- The National Organization for Rare Disorders (NORD) focused a spotlight on individuals and families who display great courage as they live with rare diseases at its Portraits of Courage Celebration last night. http://photos.prnewswire.com/prnvar/20140509/86217 During the program, Brooke and Brielle Kennedy of Michigan, ages 5 and 6, who have a rare disease known as spinal muscular atrophy, put a medal around the neck of Representative Fred...

2011-02-28 04:59:00

Canadian Association of PNH Patients raises the volume on plea for access to life-saving treatment To view the Social Media Release, click here: http://smr.newswire.ca/en/canadian-association-of-pnh-patients/patients-with-rare-blood-disease-turn-to-social-media TORONTO, Feb. 28 /PRNewswire/ - With so few people affected by rare diseases, how does a group of less than 90 patients across Canada make their voices heardon a life-and-death issue such as access to treatment? Barry...

2010-10-04 13:48:00

- Dr. Monica Bessler Launches New Center to Study, Treat Bone Marrow Failure - PHILADELPHIA, Oct. 4 /PRNewswire-USNewswire/ -- One of the world's leading experts in bone marrow failure and related blood disorders recently joined The Children's Hospital of Philadelphia. Hematology researcher Monica Bessler, M.D., Ph.D., arrived at the hospital this summer to establish a new program, the Pediatric and Adult Comprehensive Bone Marrow Failure Center. Dr. Bessler becomes the first person to...

2009-01-05 05:30:00

Alexion Licenses PDL's Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (Nasdaq: PDLI) and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris(R) (eculizumab) and PDL's patents known as the Queen et al....

2008-12-09 06:00:00

CHESHIRE, Conn., Dec. 9 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), was observed by investigators to reduce blood measures associated with undiagnosed blood clots and inflammation in patients with PNH. A separate study found that Soliris was observed to reduce indicators of pulmonary artery hypertension (PAH) in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a new...

2008-12-08 12:30:00

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86 percent reduction (P<0.001). Key secondary endpoints including fatigue (P<0.001) and transfusions/anemia...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related